Type 1 Gaucher Disease

Rare Diseases
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
Elelyso 60 units/kgPhase 41 trial
Active Trials
NCT03021941Withdrawn0Est. Jun 2020
Amicus Therapeutics
Amicus TherapeuticsPA - Philadelphia
1 program
1
AT2101Phase 11 trial
Active Trials
NCT00875160TerminatedEst. Jul 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerElelyso 60 units/kg
Amicus TherapeuticsAT2101

Clinical Trials (2)

NCT03021941PfizerElelyso 60 units/kg

Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease

Start: Jul 2019Est. completion: Jun 20200
Phase 4Withdrawn

A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101

Start: Apr 2009Est. completion: Jul 2009
Phase 1Terminated

Related Jobs in Rare Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space